Pharmaceutical

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor.

Oct 16, 2024 - 04:00
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor.
Read the original article

Tags:

Previous Article

Hanmi and MEDiC ink cancer biomarker collaboration deal

Next Article

Bayer applies for EU approval of menopause drug elinzanetant

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

With little FDA oversight, melatonin supplements vary widely in actual dosage, study finds

With little FDA oversight, melatonin supplements vary w...

Apr 25, 2023

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat urothelial cancer

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat ...

Dec 2, 2023

First pediatric study to test neutralizing antibodies against HIV shows promise

First pediatric study to test neutralizing antibodies a...

Jul 6, 2023